NCT03188523View on ClinicalTrials.gov

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

May 21, 2018

Study Completion Date

June 4, 2018

Conditions
HIV-1 Infection
Interventions
DRUG

MK-8504

After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.

Trial Locations (2)

Unknown

Charite Research Organisation GmbH. ( Site 0002), Berlin

St Stephen's Clinical Research ( Site 0001), London

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03188523 - Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) | Biotech Hunter | Biotech Hunter